当前位置: X-MOL 学术J. Food Drug Anal. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Rubiscolin-6 activates opioid receptors to enhance glucose uptake in skeletal muscle
Journal of Food and Drug Analysis ( IF 3.6 ) Pub Date : 2019-01-01 , DOI: 10.1016/j.jfda.2018.06.012
Timothy Sean Kairupan 1, 2 , Kai-Chun Cheng 1 , Akihiro Asakawa 1 , Haruka Amitani 1 , Takakazu Yagi 3 , Koji Ataka 1 , Natasya Trivena Rokot 1 , Nova Hellen Kapantow 4 , Ikuo Kato 5 , Akio Inui 1
Affiliation  

Rubiscolin-6 is an opioid peptide derived from plant ribulose bisphosphate carboxylase/oxygenase (Rubisco). It has been demonstrated that opioid receptors could control glucose homeostasis in skeletal muscle independent of insulin action. Therefore, Rubiscolin-6 may be involved in the control of glucose metabolism. In the present study, we investigated the effect of rubiscolin-6 on glucose uptake in skeletal muscle. Rubiscolin-6-induced glucose uptake was measured using the fluorescent indicator 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxyglucose (2-NBDG) in L6 and C2C12 cell lines. The protein expressions of glucose transporter 4 (GLUT4) and AMP-activated protein kinase (AMPK) in L6 cells were observed by Western blotting. The in vivo effects of rubiscolin-6 were characterized in streptozotocin (STZ)-induced diabetic rats. Rubiscolin-6 induced a concentration-dependent increase in glucose uptake levels. The increase of phospho-AMPK (pAMPK) and GLUT4 expressions were also observed in L6 and C2C12 cells. Effects of rubiscolin-6 were blocked by opioid receptor antagonists and/or associated signals inhibitors. Moreover, Rubiscolin-6 produced a dose-dependent reduction of blood glucose and increased GLUT4 expression in STZ-induced diabetic rats. In conclusion, rubiscolin-6 increases glucose uptake, potentially via an activation of AMPK to enhance GLUT4 translocation after binding to opioid receptors in skeletal muscle.

中文翻译:

Rubiscolin-6 激活阿片受体以增强骨骼肌中的葡萄糖摄取

Rubiscolin-6 是一种源自植物核酮糖二磷酸羧化酶/加氧酶 (Rubisco) 的阿片肽。已经证明,阿片受体可以控制骨骼肌中的葡萄糖稳态,而与胰岛素作用无关。因此,Rubiscolin-6 可能参与了糖代谢的控制。在本研究中,我们研究了 rubiscolin-6 对骨骼肌葡萄糖摄取的影响。使用 L6 中的荧光指示剂 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose (2-NBDG) 测量 Rubiscolin-6 诱导的葡萄糖摄取和 C2C12 细胞系。Western blotting观察L6细胞中葡萄糖转运蛋白4(GLUT4)和AMP活化蛋白激酶(AMPK)的蛋白表达。rubiscolin-6 的体内作用在链脲佐菌素 (STZ) 诱导的糖尿病大鼠中进行了表征。Rubiscolin-6 诱导葡萄糖摄取水平的浓度依赖性增加。在 L6 和 C2C12 细胞中也观察到磷酸化 AMPK (pAMPK) 和 GLUT4 表达的增加。rubiscolin-6 的作用被阿片受体拮抗剂和/或相关信号抑制剂阻断。此外,Rubiscolin-6 在 STZ 诱导的糖尿病大鼠中产生剂量依赖性的血糖降低和 GLUT4 表达增加。总之,rubiscolin-6 增加葡萄糖摄取,可能通过激活 AMPK 以增强 GLUT4 在与骨骼肌中的阿片受体结合后的易位。rubiscolin-6 的作用被阿片受体拮抗剂和/或相关信号抑制剂阻断。此外,Rubiscolin-6 在 STZ 诱导的糖尿病大鼠中产生剂量依赖性的血糖降低和 GLUT4 表达增加。总之,rubiscolin-6 增加葡萄糖摄取,可能通过激活 AMPK 以增强 GLUT4 在与骨骼肌中的阿片受体结合后的易位。rubiscolin-6 的作用被阿片受体拮抗剂和/或相关信号抑制剂阻断。此外,Rubiscolin-6 在 STZ 诱导的糖尿病大鼠中产生剂量依赖性的血糖降低和 GLUT4 表达增加。总之,rubiscolin-6 增加葡萄糖摄取,可能通过激活 AMPK 以增强 GLUT4 在与骨骼肌中的阿片受体结合后的易位。
更新日期:2019-01-01
down
wechat
bug